PL441816A1 - Kompozycja farmaceutyczna zawierająca inhibitor białka GGT1 oraz antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu - Google Patents

Kompozycja farmaceutyczna zawierająca inhibitor białka GGT1 oraz antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu

Info

Publication number
PL441816A1
PL441816A1 PL441816A PL44181622A PL441816A1 PL 441816 A1 PL441816 A1 PL 441816A1 PL 441816 A PL441816 A PL 441816A PL 44181622 A PL44181622 A PL 44181622A PL 441816 A1 PL441816 A1 PL 441816A1
Authority
PL
Poland
Prior art keywords
cysltr1
cancer
treatment
pharmaceutical composition
composition containing
Prior art date
Application number
PL441816A
Other languages
English (en)
Inventor
Katarzyna Ewa SOBIERAJSKA
Wojciech Michał CISZEWSKI
Original Assignee
Uniwersytet Medyczny w Łodzi
Sobierajska Katarzyna Ewa
Ciszewski Wojciech Michał
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny w Łodzi, Sobierajska Katarzyna Ewa, Ciszewski Wojciech Michał filed Critical Uniwersytet Medyczny w Łodzi
Priority to PL441816A priority Critical patent/PL441816A1/pl
Priority to PCT/IB2023/057151 priority patent/WO2024018334A1/en
Priority to EP23753962.2A priority patent/EP4558139A1/en
Publication of PL441816A1 publication Critical patent/PL441816A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna zawierająca inhibitor białka GTT1 i antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu.
PL441816A 2022-07-22 2022-07-22 Kompozycja farmaceutyczna zawierająca inhibitor białka GGT1 oraz antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu PL441816A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL441816A PL441816A1 (pl) 2022-07-22 2022-07-22 Kompozycja farmaceutyczna zawierająca inhibitor białka GGT1 oraz antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu
PCT/IB2023/057151 WO2024018334A1 (en) 2022-07-22 2023-07-12 Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer
EP23753962.2A EP4558139A1 (en) 2022-07-22 2023-07-12 Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441816A PL441816A1 (pl) 2022-07-22 2022-07-22 Kompozycja farmaceutyczna zawierająca inhibitor białka GGT1 oraz antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu

Publications (1)

Publication Number Publication Date
PL441816A1 true PL441816A1 (pl) 2024-01-29

Family

ID=87569894

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441816A PL441816A1 (pl) 2022-07-22 2022-07-22 Kompozycja farmaceutyczna zawierająca inhibitor białka GGT1 oraz antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu

Country Status (3)

Country Link
EP (1) EP4558139A1 (pl)
PL (1) PL441816A1 (pl)
WO (1) WO2024018334A1 (pl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130085168A1 (en) * 2008-02-04 2013-04-04 Marie H. Hanigan Gamma-glutamyl transpeptidase inhibitors and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
EP3328376A4 (en) * 2015-07-31 2019-03-13 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130085168A1 (en) * 2008-02-04 2013-04-04 Marie H. Hanigan Gamma-glutamyl transpeptidase inhibitors and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
K. M. LEMBERG ET AL.:: "Mol Cancer Ther. 2018; 17(9): 1824-1832", "WE'RE NOT "DON" YET: OPTIMAL DOSING AND PRODRUG DELIVERY OF 6-DIAZO-5-OXO-L-NORLEUCINE" *
K. R. HUBER ET AL.: "Br J Cancer. 1987; 55(6): 653-656", "CELL CYCLE PHASE PERTURBATIONS BY 6-DIAZO-5-OXO-L-NORLEUCINE AND ACIVICIN IN NORMAL AND NEOPLASTIC HUMAN CELL LINES" *
K. SUKNUNTHA ET AL.:: "Asian Pac J Cancer Prev. 2018; 19(3): 833-837", "LEUKOTRIENE RECEPTOR ANTAGONISTS INHIBIT MITOGENIC ACTIVITY IN TRIPLE NEGATIVE BREAST CANCER CELLS" *

Also Published As

Publication number Publication date
EP4558139A1 (en) 2025-05-28
WO2024018334A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
CY1125065T1 (el) Αναστολεις mcl-1
CL2021002666S1 (es) Pieza para aparato de aseo personal. (divisional solicitud no. 202002626)
MX2021005012A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.
CR8932A (es) Composicion de anticuerpo her2
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP4212524A4 (en) Cd73 inhibitor and application thereof in medicine
BRPI0409910A (pt) métodos para o tratamento de doenças relacionadas com interleucina-6
CO2022017690A2 (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
DK4039688T3 (da) Substitueret pyrrolopyrimidin og pyrazolopyrimidin som brutons tyrosinkinase- (btk) nedbrydere
EP1569640A4 (en) COMBINATIONS OF PEROXISOM PROLIFERATOR ACTIVATED ALPHA RECEPTOR AGONISTS AND SELECTIVE CYCLOOXYGENASE 2 INHIBITORS AND THEIR THERAPEUTIC USE
FR2848116B1 (fr) Composition cosmetique comprenant un inhibiteur des metallo-proteinases et un lipopeptide.
CL2025003071A1 (es) Formas cristalinas de inhibidores de ras, composiciones que las contienen y su uso.
MX2025007786A (es) Compuestos organicos como inhibidores de nlrp3
CO2023012342A2 (es) Inhibidores de enzimas
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
SE0302488D0 (sv) New combination
NO20056131L (no) En farmasoytisk sammensetning som innbefatter en P2X7-reseptorantagonist og en tumornekrosefaktor alfa
CL2025003070A1 (es) Formas cristalinas de un inhibidor de ras.
PL441816A1 (pl) Kompozycja farmaceutyczna zawierająca inhibitor białka GGT1 oraz antagonistę receptora CysLTR1 oraz jej zastosowanie w leczeniu inwazyjnych stadiów nowotworu
CY1115255T1 (el) Χρηση αναστολεων αποακετυλασης ιστονων για την φροντιδα philadelphia-αρνητικων μυελοπολλαπλασιαστικων συνδρομων
BR112022015473A2 (pt) Inibidor de igfbp5 e/ou de pelo menos um de seus receptores, polinucleotídeo isolado, composição farmacêutica e uso do mesmo
PL445003A1 (pl) Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie
PL441358A1 (pl) Inhibitor aktywności transportera ABCC1 do zastosowania w leczeniu inwazyjnych stadiów nowotworu poprzez hamowanie ich zdolności inwazyjnych oraz kompozycja farmaceutyczna zawierająca taki inhibitor
CU20200015A7 (es) Composición farmacéutica y kit que comprenden anticuerpos anti-tnf alpha